Visualitza per autor "Bücklein, Veit"
Ara mostrant els elements 1-4 d 4
-
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
Perez, Ariel; Jurinovic, Vindi; Holtick, Udo; Rejeski, Kai; IACOBONI, GLORIA; Bücklein, Veit (Wolters Kluwer Health, 2023-07-11) -
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
Burchert, Andreas; SESQUES, Pierre; Fransecky, Lars; Rejeski, Kai; IACOBONI, GLORIA; Barba, Pere; Bücklein, Veit (American Society of Hematology, 2022-08-23) -
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
Perez, Ariel; Blumenberg , Viktoria; Bücklein, Veit; Völkl, Simon; Rejeski, Kai; IACOBONI, GLORIA; Barba, Pere (American Association for the Advancement of Science, 2023-09-22) -
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
Perez, Ariel; Iacoboni García-Calvo, Gloria; Penack, Olaf; Jentzsch, Liv; Carpio Segura, Cecilia Carmen; Barba Suñol, Pere; Rejeski, Kai; Bücklein, Veit (BMJ, 2022-05)